Teresa Bruni

Teresa Bruni

Auto-generated profile, based on publicly available information

Teresa Bruni

Pulmonology Division, ASST Crema – Ospedale Maggiore, Crema

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 January 2018 in Expert Opinion on Pharmacotherapy
Verified
Journal Article
Closed access
FVfrancesco varone
francesco varone
GSGiacomo Sgalla
Giacomo Sgalla
BIBruno Iovene
Bruno Iovene
TBTeresa Bruni
Teresa Bruni
LRLuca Richeldi
Luca Richeldi
Idiopathic Pulmonary Fibrosis (IPF) is an interstitial lung disease characterized by the progressive loss of pulmonary function, ultimately leading to respiratory failure and death. Two novel compounds, nintedanib and pirfenidone, have shown efficacy in reducing the rate of decline of lung function in IPF patients. The multiple tyrosine kinase inhibitor nintedanib has extensively being studied as a potential angiogenesis inhibitor in clinical against various neoplastic disorders. Afterwards, this compound was successfully tested in IPF. Areas covered: Herein, the authors review the working mechanisms of nintedanib, its pharmacological profile, and its efficacy and safety for patients with IPF. Expert opinion: Nintedanib has shown to be safe and effective in patients with IPF, with a favorable long-term safety profile. There is a lack of comparative trials of pirfenidone and nintedanib, and the choice of treatment is left to the physicians' judgement. Future directions of nintedanib use are represented by the treatment of progressive fibrosing interstitial lung disease other than IPF, IPF with advanced functional impairment, and lung fibrosis secondary to connective tissue diseases. A promising safety profile for the combinational use of nintedanib and pirfenidone in IPF has also recently emerged.

1 August 2020 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Open access
TBTeresa Bruni
Teresa Bruni
ALAjit Lalvani
Ajit Lalvani
LRLuca Richeldi
Luca Richeldi

5 May 2017 in Respiration
Verified
Journal Article
Closed access
DMDaniele Magnini
Daniele Magnini
GMGiuliano Montemurro
Giuliano Montemurro
BIBruno Iovene
Bruno Iovene
LTLinda Tagliaboschi
Linda Tagliaboschi
RGRafael Emanuele Gerardi
Rafael Emanuele Gerardi
LRLuca Richeldi
Luca Richeldi
Idiopathic pulmonary fibrosis (IPF) is a specific form of chronic, progressive fibrosing interstitial pneumonia of unknown causes. Current diagnostic criteria are based on radiological, clinical, and histopathological features but, unfortunately, still many patients remain undiagnosed. Two currently approved therapies, pirfenidone and nintedanib, slow down disease progression but failed to block or revert it. On the other hand, many of the therapeutic agents tested in several clinical trials have not given satisfactory answers, probably due to the pathological heterogeneity of the disease. A growing number of studies show that IPF phenotype is the common clinical outcome of a variety of different pathophysiological mechanisms that identify disease subgroups characterised by specific genetic and molecular biomarkers (endotypes). The precision medicine approach is identifying and analysing the complex system of genetic, molecular, environmental, and behavioural variables underlying the development of the disease and the response to therapy. These molecular pathways are potential targets for novel agents and useful diagnostic, prognostic, and theragnostic biomarkers. We outline the status of knowledge in this field by discussing the complex pathogenetic pathways underlying different disease subgroups and assessing a stratification approach to novel therapeutic agents based on these endotypes.

1 June 2020 in Breathe
Verified
Journal Article
Open access
PDF file
TBTeresa Bruni
Teresa Bruni
FVFrancesco Varone
Francesco Varone
Nintedanib shows a statistically significant effect on lung function decay in patients with ILD secondary to systemic sclerosis, but no effect on skin fibrosis and on health-related quality of lifehttp://bit.ly/2vfJRj7

1 October 2020 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Open access
TBTeresa Bruni
Teresa Bruni
ALAjit Lalvani
Ajit Lalvani
LRLuca Richeldi
Luca Richeldi

3 October 2023 in Monaldi Archives for Chest Disease
Verified
Journal Article
Open access
PDF file
DMDaniele Magnini
Daniele Magnini
EBEmilio Bria
Emilio Bria
ACAlessandra Cancellieri
Alessandra Cancellieri
VLVanina Livi
Vanina Livi
FLFausto Leoncini
Fausto Leoncini
Rocco TrisoliniRocco Trisolini
Rocco Trisolini
Cavitating lung tumors occur in approximately 10-15% of the patients, are more commonly associated with squamous histology, and are typically located in the lung parenchyma. Herein we describe an exceedingly rare series of 5 patients, 4 of whom treatment-naïve, whose tumor caused the disruption of the normal airway anatomy at the level of lobar or segmental bronchi, leading to the formation of an endoscopically-visible cavity which ended up in the lung parenchyma or even into the pleural space. Sex (3 males, 2 females), smoking habit (2 never smokers, 2 former smokers, 1 current smoker), and histology (3 adenocarcinoma, 2 squamous cell carcinoma) were heterogeneous, but the 4 patients treatment-naïve presented with metastatic disease, poor ECOG performance status, similar clinical complaints of long duration, and lack of actionable mutations. The only patient who exhibited a meaningful response to treatment had the lowest symptoms’ duration, the smallest size of the cavitated mass, and the best performance status at the time of diagnosis. This series provides the first comprehensive description of a rare presentation of lung cancer characterized by similar clinical complaints, delayed diagnosis and poor prognosis.